Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21320375 | 0.78 | RECQL (0.39) | RECQLGAAPTPRC | |
| SCHEMBL23332545 | 0.78 | TDP1 (0.46) | HPGDRECQLGAAALDH1A1MAPT | |
| SCHEMBL6576933 | 0.78 | FAAH (0.49) | FAAHHPGDSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL23332055 | 0.78 | RECQL (0.44) | RECQLGAAPTPRC | |
| SCHEMBL1688820 | 0.77 | ALDH1A1 (0.40) | FAAHSMN1; SMN2GAAALDH1A1HSD17B10 | |
| SCHEMBL13292141 | 0.77 | RECQL (0.38) | RECQLGAAPTPRC | |
| SCHEMBL23643340 | 0.77 | FAAH (0.47) | FAAHHPGDSMN1; SMN2RECQLGAA | |
| SCHEMBL6575441 | 0.77 | RECQL (0.38) | RECQLGAAPTPRC | |
| SCHEMBL20829083 | 0.76 | RECQL (0.41) | RECQLGAAPTPRC | |
| SCHEMBL7376338 | 0.76 | RECQL (0.41) | RECQLGAAPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777498-B1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
| EP-0777498-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996002274-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | DCLRE1B, RNASE1, DCLRE1A | FAAH 4856/4885HPGD 4100/4885SMN1; SMN2 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.